Infliximab use in Crohn's disease

Expert Opinion on Biological Therapy

Volumn 5, Issue 4, 2005, Pages 589-599

  Bewtra, Meenakshi ^a   Lichtenstein, Gary R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Crohn's disease; Inflammatory bowel disease; Infliximab

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYTOKINE; DIPHENHYDRAMINE; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; LEVOFLOXACIN; MERCAPTOPURINE; METRONIDAZOLE; MLN 02; NATALIZUMAB; ORNIDAZOLE; PARACETAMOL; PREDNISONE; QUINOLONE DERIVATIVE; RIFAXIMIN; SEMAPIMOD; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ABSCESS; ANAPHYLAXIS; ASPERGILLOSIS; BRONCHITIS; CELLULITIS; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DYSPHAGIA; DYSPNEA; EDEMA; ENDOSCOPY; ENTERITIS; FEVER; HEADACHE; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; INFLAMMATION; LEUKOCYTOSIS; LISTERIOSIS; LONG TERM CARE; LUNG CANCER; META ANALYSIS; MYALGIA; MYCOSIS; NAUSEA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PERITONITIS; PHARYNGITIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POLYARTHRITIS; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SEDATION; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SINUSITIS; SORE THROAT; SYSTEMATIC REVIEW; THORAX PAIN; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS;

EID: 17844388103     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.4.589     Document Type: Review

References (65)

1. BLAM ME, STEIN RB, LICHTENSTEIN GR: Integrating antitumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am. J. Gastroenterol. (2001) 96(7):1977-1997.
2. HAY JW, HAY AR: Inflammatory bowel disease: cost-of-illness. J. Clin. Gastroenterol. (1992) 14:309-317.
3. MODIGLIANI R, MARY JY, SIMON JF et al.: Clinical, biological, and endoscopic picture of attacks of Crohns disease. Evolution on prednisolone. Gastroenterology (1990) 98:811-818.
4. OLAISON B, SJODAHL R, TAGESSON C: Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut (1990) 31:324-328.
5. LANDI B, ANH TN, CORTOT A et al.: Endoscopic monitoring of Crohns disease treatment: a prospective, randomized clinical trial. Gastroenterology (1992) 102:1647-1653.
6. SANDBORN W, SUTHERLAND L, PEARSON D et al.: Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev. (2000):CD000545.
7. SANDBORN WJ, FAUBION WA: Biologics in inflammatory bowel disease: how much progress have we made? Gift (2004) 53:1366-1373.
8. AGGARWAL BB, VILCEK J: Tumour Necrosis Factors: Structure, Function, und Mechanism of Action. Aggarwal BB, Vilcek J (Eds), Marcel Dekker, Inc., New York, NY, USA (1992).
9. BEUTLER B: Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. Bender B (Ed.), Raven Press, New York, NY, USA (1992).
10. FIERS W: Tumor necrosis factor: characterization at the molecular, cellular and in vivo level. FEBS Lett. (1991) 285:199-212.
11. BEUTLER B, CERAMI A: The biology of cachectin/TNF-a primary mediator of the host response. Annu. Rev. Immunol. (1989) 7:625-655.
12. PENDER SL, TICKLE SP, DOCHERTY AJ, HOWIE D, WATHEN NC, MACDONALD TT: A major role for matrix metalloproteinases in T cell injury in the gut. J. Immunol. (1997) 158:1582-1590.
13. PENDER SL, FELL JM, CHAMOW SM, ASHKENAZI A, MACDONALD TT: A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J. Immunol. (1998) 160:4098-4103.
14. BRENNAN FM, CHANTRY D, JACKSON A, MAINI R, FELDMAN M: Inhibitory effect of TNF-a antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 2(8657):244-247.
15. HORIE Y, CHIBA M, SUZUKI T et al.: Induction of major histocompatability complex class II antigens on human colonic epithelium by interferon-gamma, tumor necrosis factor-alpha, and interleukin-2. J. Gastroenterol. (1998) 39(1):30-47.
16. KAISER GC, POLK DB: Tumor necrosis factor alpha regulates proliferation in a mouse intestinal cell line. Gastroenterology (1997) 112:1231-1240.
17. WEDEMEYER J, LORENTZ A, GOKE M et al.: Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa. Gut (1999) 44:629-635.
18. MURCH SH, LAMKIN VA, SAVAGE MO, WALKER-SMITH JA, MACDONALD TT: Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut (1991) 32:913-917.
19. VAN DEVENTER SJ: Tumour necrosis factor and Crohn's disease. Gut (1997) 40:443-448.
20. BRAEGGER CP, NICHOLLS S, MURCH SH, STEPHENS S, MACDONALD TT: Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet (1992) 339:89-91.
21. CAPPELLO M, KESHAV S, PRINCE C, JEWELL DP, GORDON S: Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridization. Gut (1992) 33:1214-1219.
22. DIONNE S, HISCOTT J, D'AGATA I, DUHAIME A, SEIDMAN EG: Quantitative PCR analysis of TNF-alpha, and IL-I beta mRNA levels in pediatric IBD mucosal biopsies. Dig. Dis. Sci. (1997) 42:1557-1566.
23. OBERMEIER F, KOJOUHAROFF G, HANS W, SCHOLMERICH J, GROSS V, FALK W: IFN-gamma (INF-γ)-, and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin. Exp. Immunol. (1999) 116:238-245.
24. SIEGEL SA, SHELY DJ, NAKADA MT et al.: The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protests transgenic mice from cachexia and TNF lethality in vivo. Chemokine (1995) 7:15-25.
25. SCALLON BJ, MOORE MA, TRINH H, KNIGHT DM, GHRAYEB J: Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine (1995) 7:251-259.
26. VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohns disease. Gastroenterology (2003) 124(7):1774-1785.
27. MOUSER JF, HYAMS JS: Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin. Ther. (1999) 21:932-942.
28. NO AUTHORS LISTED: Infliximnb (Remicade) for Crohn's disease. Med. Lett. Drugs Ther. (1999) 41(1047):19-20.
29. COMERFORD LW, BICKSTON SJ: Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol. Clin. North Am. (2004) 33(2):387-406.
30. VAN DULLEMAN HM, VAN DEVENTER SJ, HOMMES DW et al.: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109:129-135.
31. MCCABE RP, WOODY J, VAN DEVENTER SJ et al.: A multiecenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology (1996) 110(Suppl. 4):A962.
32. TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody CA2 to tumor necrosis factor a for Crohn's disease. N. Engl. J. Med. (1997) 337:1029-1035.
33. RUTGEERTS P, D'HAENS G, TARGAN S et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 117:761-769.
34. HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet (2002) 359:1541-1549.
35. PRESENT DH, RUTGEERTS P, TARGAN S et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. (1999) 340:1398-1405.
36. SANDS BE, ANDERSON FH, BERNSTEIN CN et al.: Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. (2004) 350:876-885.
37. BAERT FJ, D'HAENS GR, PEETERS M et al.: Tumor necrosis factor a antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn's ileocolitis. Gastroenterology (1999) 116:22-28.
38. D'HAENS G, VAN DEVENTER S, VAN HOGEZAND R et al.: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology (1999) 116:1029-1034.
39. RUTGEERTS P, MALCHOW H, VATN MH et al.: Mucosal healing in Crohn's disease patients is associated with reduction in hospitalizations and surgeries. Gastroenterology (2002) 123:M2138.
40. RICART E, PANACCIONE R, LOFTUS E, TREMAINE W, SANDBORN W: Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am. J. Gastroenterol. (2001) 96:722-729.
41. COHEN RD, TSANG JF, HANAUER SB: Infliximab for Crohn's disease: first anniversary clinical experience. Am. J. Gastroenterol. (2000) 95:3469-3477.
42. COLOMBEL JF, RICART E, LOFTUS EV et al.: Management of Crohn's disease of the ileoanal pouch with infliximab. Am. J. Gastroenterol. (2003) 98:2239-2244.
43. HELLER T, JAMES SP, DRACHENBERG C, HERNANDEZ C, DARWIN PE: Treatment of severe esophageal Crohn's disease with Infliximab. Inflamm. Bowel Dis. (1999) 5:279-282.
44. VAN DULLEMAN HM, DEJOHN E, SLORS F, TYTGAT GN, VAN DEVENTER SJ: Treatment of therapy-resistant perineal metastatic Crohn's disease after proctocolectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2: report of two cases. Dis. Colon Rectum (1998) 41:98-102.
45. BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicenter trial. Lancet (2002) 359:1187-1193.
46. BRAUN J, BRANDT J, LISTING J et al.: Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. (2003) 48(8)12224-2233.
47. TAN MH, GORDON M, LEBWOHL O, GEORGE J, LEBWOHL MG: Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch. Dermatol. (2001) 137:930-933.
48. SU CG, JUDGE TA, LICHTENSTEIN GR: Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol. Clin. North Am. (2002) 31:307-327.
49. CENTOCOR, INC.: Remicade (infliximab) for IV injection. Package insert. Malvern, PA, USA (2004).
50. COLOMBEL JF, LOFTUS EV, TREMAINE WJ et al.: The safety profile of infliximab for Crohn's disease in clinical practice: the Mayo Clinic experience in 500 patients. Gastroenterology (2003) 123:A7.
51. HANAUER SB: Review article: safety of infliximab in clinical trials. Aliment. Pharmacol. Ther. (1999) 13(Suppl. 4):16-22.
52. HANAUER SB, RUTGEERTS PJ, D'HAENS G et al.: Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment. Gastroenterology (1999) 116:A731.
53. BAERT F, NORMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. (2003) 348:601-608.
54. FEAGAN BG, SONGKAI Y, BALA M, BAO W, LICHTENSTEIN GR: The effects of infliximab maintenance therapy on health-related quality of life. Am. J. Gastroenterol. (2003) 98(10):2232-2238.
55. FARRELL RJ, ALSAHLI M, JEEN YT, FALCHUK KR, PEPERCORN MA, MICHETTI P: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology (2003) 124:917-924.
56. LJUNG T, KARLEN P, SCHMIDT D et al.: Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm Country. Gut (2004) 53(6):849-853.
57. KATZ JA, ANTONI C, KEENAN GF, SMITH DE, JACOBS SJ, LICHTENSTEIN GR: Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am. J. Gastroenterol. (2004) 99:2385-2392.
58. RUBENSTEIN JH, CHONG RY, COHEN RD: Infliximab decreases resource use among patients with Crohn's disease. J. Clin. Gastroenterol. (2002) 35:151-156.
59. RUTGEERTS P, FEAGAN B, LICHTENSTEIN G et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 126:402-413.
60. SANDBORN WJ, FEAGAN BG, RADFORD-SMITH G et al.: CDP571, a humanized monoclonal antibody to tumour necrosis factor a, for moderate to severe Crohn's disease: a randomized, double blind, placebo controlled trial. Gut (2004) 53:1485-1493.
61. MANNON PJ, FUSS IJ, MAYER L et al.: Anti-interleukin-12 antibody for active crohn's disease. N. Engl. J. Med. (2004) 351:2069-2079.
62. PAPADAKIS KA, SHAYE OA, VASILIAUSKAS EA et al.: Safety and efficacy of adalimumab (D2E/) in Crohn's disease patients with an attenuated response to infliximab. Am. J. Gastroenterol (2005) 100(1):75-79.
63. SANDS BE, REMAINE WJ, SANDBORN WJ et al.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis. (2001) 7:83-88.
64. PROBERT CS, HEARING SD, SCHREIBER S et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomized controlled trial. Gut (2003) 52:998-1002.
65. OCHSENKUHN T, SACKMANN M, GOKE B: Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur. J. Gastroenterol. Hepatol. (2004) 16(11):1167-1171.